Metropolitan Life Insurance Company (MetLife)’s Regulus Therapeutics RGLS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-267	Closed	-$93K	–	2649
2016 Q2	$93K	Buy	267 +64	+32%	+$45.8K	﹤0.01%	2601
2016 Q1	$169K	Buy	203 +20	+11%	+$15.9K	﹤0.01%	2270
2015 Q4	$191K	Buy	183 +4	+2%	+$4.01K	﹤0.01%	2298
2015 Q3	$141K	Hold	179	–	–	﹤0.01%	2508
2015 Q2	$236K	Buy	179 +80	+81%	+$129K	﹤0.01%	2287
2015 Q1	$201K	Hold	99	–	–	﹤0.01%	2051
2014 Q4	$191K	Buy	+99	New	+$176K	﹤0.01%	2448

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RGLS Position: Q3 2016 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Regulus Therapeutics (RGLS) in Q3 2016, closing a stake of 267 shares — an estimated $93K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RGLS in Q4 2014 and held it in 7 quarters. The position peaked at $236K in Q2 2015. 83 funds tracked by Wall St. Rank hold RGLS as of Q3 2016.

Metropolitan Life Insurance Company (MetLife) reported no remaining Regulus Therapeutics position as of Q3 2016 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 267 Regulus Therapeutics shares in Q3 2016, an estimated $93K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Regulus Therapeutics in Q4 2014 and held it in 7 quarters.
Metropolitan Life Insurance Company (MetLife)'s Regulus Therapeutics position peaked at $236K in Q2 2015.
83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2016.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2016, filed 15 Nov 2016.